Press release
Duchenne Muscular Dystrophy Market Size Predicted to Hit USD 2.1 billion by 2031 at 4.7% CAGR, Says AMR
Duchenne Muscular Dystrophy Market Size
This report provides a comprehensive overview of the Duchenne Muscular Dystrophy Market, including an in-depth analysis of market trends, key segments, investment opportunities, value chain analysis, regional landscape, and competitive scenarios. It offers valuable insights for established market players, new entrants, investors, and other stakeholders to devise effective strategies and make informed decisions to enhance their market position. The report is a valuable resource for anyone seeking to gain a deeper understanding of the Duchenne Muscular Dystrophy Market and its growth potential in the future.
Rise in the incidence of the Duchenne muscular dystrophy (DMD) and surge in need for better healthcare services drive the growth of the global Duchenne muscular dystrophy market. However, inflated cost of treatments for Duchenne muscular dystrophy restricts the market growth. On the other hand, increase in government spending on the pharmaceutical and biotechnology sectors in developing countries, the development of healthcare infrastructure, and rise in demand for innovative treatments for Duchenne muscular dystrophy present new opportunities in the coming years.
Get Sample PDF Report with Graphs and Figures Here: https://www.alliedmarketresearch.com/request-sample/16015
Top Companies Of Duchenne Muscular Dystrophy (DMD)
• F Hoffmann-La Roche AG
• FibroGen, Inc
• GlaxoSmithKline plc
• Italfarmaco S.p.A.
• Nippon Shinyaku Co., Ltd
• Pfizer Inc.
• PTC Therapeutics
• Santhera Pharmaceuticals Inc
• Sarepta therapeutics
• Wave life sciences ltd.
• ABBOTT LABORATORIES
Duchenne Muscular Dystrophy (DMD) Market Size Segmentation: -
Based on therapeutic area, the molecular-based therapies segment held the highest market share in 2021, accounting for around three-fifths of the global Duchenne muscular dystrophy market, and is estimated to maintain its leadership status throughout the forecast period. In addition, the same segment is projected to manifest the highest CAGR of 5.0% from 2022 to 2031, owing to R & D activities for exon skipping drugs, strong product pipeline and significant product launch by key players. The report also discusses steroid therapy segment.
Based on distribution channel, the hospital pharmacies segment accounted for the largest share in 2021, contributing to more than three-fifths of the global Duchenne muscular dystrophy market, and is projected to maintain its lead position during the forecast period. This is owing to significant rise in the number of diagnosis through hospitals. However, the drug store & retail pharmacies segment is expected to portray the largest CAGR of 5.4% from 2022 to 2031, owing to the rise in the approval of drugs and their availability in drug store & retail pharmacies.
Based on region, North America held the highest market share in terms of revenue in 2021, accounting for more than half of the global Duchenne muscular dystrophy market, and is likely to dominate the market during the forecast period. This is owing to technological advancements in Duchenne muscular dystrophy treatment and presence of key players & robust hospital infrastructure in the region.
However, the Asia-Pacific region is expected to witness the fastest CAGR of 5.9% from 2022 to 2031. This is owing to rise in cases of Duchenne muscular dystrophy, approval of drugs, development of healthcare infrastructure, and increase in investments projects in the region.
Purchase the Report: https://www.alliedmarketresearch.com/purchase-enquiry/16015
Key Benefits For Stakeholders
• The report provides an in-depth analysis of the Duchenne muscular dystrophy market size along with the current trends and future estimations to elucidate imminent investment pockets.
• It offers market analysis from 2022 to 2031, which is expected to enable stakeholders to capitalize on prevailing opportunities in the Duchenne muscular dystrophy market.
• A comprehensive analysis on region assists to understand the regional market, facilitate strategic business planning, and determine prevailing opportunities.
• The profiles and growth strategies of key players are thoroughly analyzed to understand competitive outlook of the global Duchenne muscular dystrophy treatment market growth.
Our Market Research Solution Provides You Answer to Below Mentioned Question:
• Which are the driving factors responsible for the growth of market?
• Which are the roadblock factors of this market?
• What are the new opportunities, by which market will grow in coming years?
• What are the trends of this market?
• Which are main factors responsible for new product launch?
• How big is the global & regional market in terms of revenue, sales and production?
• How far will the market grow in forecast period in terms of revenue, sales and production?
• Which region is dominating the global market and what are the market shares of each region in the overall market in 2022?
• How will each segment grow over the forecast period and how much revenue will these segments account for in 2030?
• Which region has more opportunities?
By Region Outlook
• North America
(U.S., Canada, Mexico)
• Europe
(Germany, France, UK, Italy, Spain, Rest of Europe)
• Asia-Pacific
(Japan, China, India, Rest of Asia-Pacific)
• LAMEA
(Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Contact Details:
David Correa
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
help@alliedmarketresearch.com
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Duchenne Muscular Dystrophy Market Size Predicted to Hit USD 2.1 billion by 2031 at 4.7% CAGR, Says AMR here
News-ID: 4493453 • Views: …
More Releases from Allied Market Research (AMR)
Ambulance Services Market Size (USD 94.2 Billion by 2031): Growth Prospects, Inn …
Allied Market Research has published a study report with the title Ambulance Services Market Size was Valued at USD 40.6 billion in 2021 and is Projected to Garner USD 94.2 billion by 2031, registering a CAGR of 8.9% from 2022 to 2030. The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and evolving market trends. The…
Petroleum Resins Market Report Highlighting Recent Developments and Growth Updat …
The global petroleum resins market is witnessing steady growth, driven by rising demand across construction, packaging, and personal hygiene industries.
According to a report by Allied Market Research, the market was valued at $2.5 billion in 2018 and is projected to reach $4.0 billion by 2028, growing at a CAGR of 5.2% (2023-2028).
Download Sample Pages of Research Overview: https://www.alliedmarketresearch.com/request-sample/17837
What Are Petroleum Resins?
Petroleum (hydrocarbon) resins are synthetic polymers derived from petroleum by-products…
Hydrogen Market Report Outlining Growth Opportunities, Market Share and Competit …
The global hydrogen market is witnessing steady expansion, projected to grow from $155.9 billion in 2022 to $292 billion by 2032, registering a CAGR of 6.5% (2023-2032).
Driven by the global push toward clean energy, decarbonization, and sustainable industrial processes, hydrogen is rapidly becoming a cornerstone of the future energy mix.
Download Sample Pages of Research Overview: https://www.alliedmarketresearch.com/request-sample/A16583
The captive segment to maintain its lead position during the forecast period:
Based on delivery mode,…
Herbal Extract Products Market Report Analyzing Applications, Verticals & Region …
The global herbal extract products market was valued at $27,949.6 million in 2022 and is projected to reach $85,120.9 million by 2032, growing at a robust CAGR of 11.9% (2023-2032).
Driven by the rising shift toward natural, organic, and sustainable solutions, herbal extracts are gaining significant traction across industries such as food & beverages, cosmetics, and pharmaceuticals.
Download Sample Pages of Research Overview: https://www.alliedmarketresearch.com/request-sample/A161169
Prime Determinants of Growth
- Increasing consumer preference for natural…
More Releases for Duchenne
Duchenne Muscular Dystrophy (DMD) Market Growth in 2034
Market Overview
The Duchenne Muscular Dystrophy (DMD) Market is expanding rapidly as advances in genetic medicine, exon-skipping therapies, gene therapy platforms, and improved diagnostic capabilities reshape treatment options for this severe, progressive neuromuscular disorder.
DMD is caused by mutations in the dystrophin gene, leading to muscle degeneration beginning in early childhood. Growing awareness among clinicians and caregivers, widespread adoption of next-generation sequencing (NGS), and increasing availability of disease-modifying therapies have significantly strengthened…
Duchenne Muscular Dystrophy: Core Growth Enabler in the Rising Prevalence Of Chr …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Duchenne Muscular Dystrophy Industry Market Size Be by 2025?
The market size for Duchenne Muscular Dystrophy has shown significant expansion recently, burgeoning from $1.16 billion in 2024 to $1.25 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The impressive growth in the…
Rising Prevalence Of Chronic Diseases Fuels Growth In The Duchenne Muscular Dyst …
What industry-specific factors are fueling the growth of the duchenne muscular dystrophy market?
The rise in chronic diseases is projected to stimulate the expansion of the Duchenne muscular dystrophy market in the coming years. Chronic diseases are health complications that endure for a minimum of a year. Duchenne muscular dystrophy is instrumental in the increase of chronic diseases as it addresses the unique therapeutic requirements of those suffering from this genetic…
Shaping the Duchenne Muscular Dystrophy (DMD) Therapeutics Market in 2025: Bit B …
How Big Is the Duchenne Muscular Dystrophy (DMD) Therapeutics Market Expected to Be, and What Will Its Growth Rate Be?
The Duchenne muscular dystrophy (DMD) therapeutics market will grow from $11.95 billion in 2024 to $16.45 billion in 2025, at a CAGR of 37.6%. The growth is attributed to the increasing prevalence of Duchenne muscular dystrophy, rising awareness of treatment options, healthcare spending, and government initiatives.
The Duchenne muscular dystrophy (DMD) therapeutics…
Duchenne Muscular Dystrophy Pipeline Outlook Report 2024
DelveInsight's, "Duchenne Muscular Dystrophy Pipeline Insight 2024" report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Duchenne Muscular Dystrophy pipeline landscape. It covers the Duchenne Muscular Dystrophy pipeline drug profiles, including Duchenne Muscular Dystrophy clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
…
Duchenne Muscular Dystrophy Treatmcent Market
Global Duchenne Muscular Dystrophy Treatmcent Market Set for Robust Growth During Forecast Period
The global Duchenne Muscular Dystrophy Treatment Market is poised to witness significant growth at a high Compound Annual Growth Rate (CAGR) during the forecast period of 2023 to 2030. Duchenne muscular dystrophy (DMD) stands as a genetic disorder marked by progressive muscle degeneration and weakness, with therapeutics aimed at addressing the absence of dystrophin, a crucial protein in…
